Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Pharmaceuticals
EPIC: IMUC
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
ImmunoCellular Therapeutics
www.imuc.com

ImmunoCellular Therapeutics, Ltd. is a development-stage company. The Company is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. The product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat different cancers.

Full ImmunoCellular Therapeutics profile here
Pdf

ImmunoCellular expects phase 2 analysis for brain cancer vaccine by year-end 2012

7th Sep 2011, 9:58 am by Deborah Sterescu
ImmunoCellular expects phase 2 analysis for brain cancer vaccine by year-end 2012

Biotech company ImmunoCellular Therapeutics (OTCBB: IMUC) said Wednesday that its phase 2 study for its potential hugely promising brain cancer vaccine is well underway, with trial enrollment expected by the second quarter of next year.

The Los Angeles-based company's cancer vaccine, named ICT-107, is designed to treat glioblastoma multiforme, an aggressive type of brain tumour.

The vaccine uses cancer stem cells to target multiple tumour-associated antigens, which generate an antibody response from the body's own immune system.

In other words, white blood cells are primed in the lab to attach to markers present in brain tumours, and these cells are then injected back into the body, where they travel to the brain and attack tumour cells.

To date, the company has initiated the phase 2 trial in 12 centres, with plans to increase the overall number of sites to 20 or more. So far, ImmunoCellular has received approval from the Institutional Review Board for a total of 18 trial sites.

The trial is expected to enroll between 150 to 160 newly diagnosed patients to treat a total of 102 patients, with 36 subjects enrolled already.

An interim analysis from the double-blind, placebo-controlled study, which will measure the safety and efficacy of the vaccine, is anticipated by the end of 2012, the company said.

"We are pleased with the progress we have made in our Phase II trial for the treatment of glioblastoma multiforme, said president and CEO, Manish Singh, Ph.D.

"We are encouraged by the strong interest we have received from the medical community, and the role that leading oncologists are playing in supporting our efforts to enroll patients."

Indeed, the vaccine has loads of potential for the patient population. In the phase one trial, 80% of 16 patients showed a two-year overall survival rate, while 44% also showed a progression-free survival rate. Even more, six of the 16 clinical patients had no tumor recurrence, with three remaining disease-free for almost four years, while the other three had gone more than two and a half years without cancer.

The vaccine was given in addition to standard of care therapy, including surgery radiation and chemotherapy.

No treatment-related serious adverse events were observed to date, the company said.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.